HER-2低表达乳腺癌临床及影像的研究进展
Journal: Basic Medical Theory Research DOI: 10.12238/bmtr.v6i6.10975
Abstract
乳腺癌是全球女性最常见的恶性肿瘤之一,其分子分型对治疗策略和预后具有重要影响。HER-2(人表皮生长因子受体2)作为乳腺癌治疗的重要靶点,其表达水平的高低直接影响患者的治疗方案选择。近年来,随着对乳腺癌分子异质性认识的加深,HER-2低表达状态逐渐受到重视。本文综述了HER-2低表达乳腺癌的临床病理特征及影像学表现的研究进展,为临床诊断和治疗提供参考。
Keywords
乳腺癌；HER-2低表达；临床病理特征；影像学表现；研究进展
Full Text
PDF - Viewed/Downloaded: 0 TimesReferences
[1] Modi S,Jacot W,Yamashita T,etal.Trastuzumab Deruxtec an in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med.2022.387(1):9-20.
[2] Bray F,Laversanne M,Sung H,etal.Global cancer statist ics 2022:GLOBOCAN estimates of incidence and mortality world wide for 36 cancers in 185 countries. CA Cancer J Clin. 2024.74(3):229-263.
[3] Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol.2001.2(2):127-37.
[4] Cai M,Li M,Lv H,et al. HER2-low breast cancer: evolution of HER2 expression from primary tumor to distant metastases. BMC Cancer.2023.23(1):656.
[5] Wei T,Wang D,Gao S,etal.Clinicopathologic characteristi cs and prognostic significance of HER2-low expression in patients with early breast cancer: A systematic review and meta-analysis.Front Oncol.2023.13:1100332.
[6] Ma Y,Zhu M, Zhang J, Lv M, Chen X, Liu Z. Prognostic Value of the Evolution of HER2-Low Expression after Neoadjuvant Chemotherapy.Cancer Res Treat.2023.55(4):1210-1221.
[7] 李晓娜,刘松鸽,王军凯.HER－2低表达乳腺癌的临床病理特征及预后分析.中国实用医刊,2024,51(03):19-24.
[8] 白冰,张艾佳,郭新,等.HER2低表达乳腺癌的临床病理特征和预后因素分析.中国医科大学学报,2023,52(06):494-498.
[9] LiuCG,LiYF,MaTY,etal.Clinicopathological characteristi cs and prognosis of early-stage HER2 low-expression breast cancer:A single-center retrospective study. Front Oncol. 2023. 13:1130734.
[10] 康佳,吴桐.不同分子分型乳腺癌的多模态超声特征和临床病理对照研究[J].中华超声影像学杂志,2020,29(4):330-336.
[11] HasanR,BhattD,KhanS,et al.Association of Her-2 Expr ession and Clinicopathological Parameters in Colorectal Carc inoma in Indian Population. Open Access Maced J Med Sci. 2019. 7(1):6-11.
[12] 李宏,李德华,胡波.乳腺癌超声征象与Ki67、p53表达的相关性及临床意义.中国临床医学影像杂志,2015,26(5):321-324.
[13] 宋方彬,李善宝,吴珺艺,等.Ki-67、PR在Luminal型乳腺癌中的表达及预后意义.中华普通外科杂志,2017,32(9):787-788.
[14] SunL,YuDH,SunSY,ZhuoSC,CaoSS,WeiL.ExpressionsofER,PR,HER-2,COX-2, and VEGF in primary and relapsed/metastatic breast cancers.Cell Biochem Biophys.2014.68(3):511-6.
[15] 高军喜.不同分子亚型乳腺癌超声造影特征及定量参数对比研究[J].中国临床医学影像杂志,2019,30(4):261-266.
[16] LiZ,RenM,TianJ,etal.The differences in ultrasound and clinicopathological features between basal-like and normallike subtypes of triple negative breast cancer. PLoS One. 2015.10(3):e0114820.
[17] Yoon GY,Chae EY,Cha JH,etal.Imaging and Clinicopath ologic Features Associated With Pathologic Complete Response in HER2-positive Breast Cancer Receiving Neoadjuvant Chemot herapy With Dual HER2 Blockade.Clin Breast Cancer. 2020. 20(1):25-32.
[18] Bae MS,Shin SU,Ryu HS,et al. Pretreatment MR Imaging Features of Triple-Negative Breast Cancer: Association with Response to Neoadjuvant Chemotherapy and Recurrence-Free Survival.Radiology.2016.281(2):392-400.
[19] Moffa G,Galati F,Collalunga E,etal. Can MRI Biomarkers Predict Triple-Negative Breast Cancer. Diagnostics (Basel).2020.10(12):1090.
[2] Bray F,Laversanne M,Sung H,etal.Global cancer statist ics 2022:GLOBOCAN estimates of incidence and mortality world wide for 36 cancers in 185 countries. CA Cancer J Clin. 2024.74(3):229-263.
[3] Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol.2001.2(2):127-37.
[4] Cai M,Li M,Lv H,et al. HER2-low breast cancer: evolution of HER2 expression from primary tumor to distant metastases. BMC Cancer.2023.23(1):656.
[5] Wei T,Wang D,Gao S,etal.Clinicopathologic characteristi cs and prognostic significance of HER2-low expression in patients with early breast cancer: A systematic review and meta-analysis.Front Oncol.2023.13:1100332.
[6] Ma Y,Zhu M, Zhang J, Lv M, Chen X, Liu Z. Prognostic Value of the Evolution of HER2-Low Expression after Neoadjuvant Chemotherapy.Cancer Res Treat.2023.55(4):1210-1221.
[7] 李晓娜,刘松鸽,王军凯.HER－2低表达乳腺癌的临床病理特征及预后分析.中国实用医刊,2024,51(03):19-24.
[8] 白冰,张艾佳,郭新,等.HER2低表达乳腺癌的临床病理特征和预后因素分析.中国医科大学学报,2023,52(06):494-498.
[9] LiuCG,LiYF,MaTY,etal.Clinicopathological characteristi cs and prognosis of early-stage HER2 low-expression breast cancer:A single-center retrospective study. Front Oncol. 2023. 13:1130734.
[10] 康佳,吴桐.不同分子分型乳腺癌的多模态超声特征和临床病理对照研究[J].中华超声影像学杂志,2020,29(4):330-336.
[11] HasanR,BhattD,KhanS,et al.Association of Her-2 Expr ession and Clinicopathological Parameters in Colorectal Carc inoma in Indian Population. Open Access Maced J Med Sci. 2019. 7(1):6-11.
[12] 李宏,李德华,胡波.乳腺癌超声征象与Ki67、p53表达的相关性及临床意义.中国临床医学影像杂志,2015,26(5):321-324.
[13] 宋方彬,李善宝,吴珺艺,等.Ki-67、PR在Luminal型乳腺癌中的表达及预后意义.中华普通外科杂志,2017,32(9):787-788.
[14] SunL,YuDH,SunSY,ZhuoSC,CaoSS,WeiL.ExpressionsofER,PR,HER-2,COX-2, and VEGF in primary and relapsed/metastatic breast cancers.Cell Biochem Biophys.2014.68(3):511-6.
[15] 高军喜.不同分子亚型乳腺癌超声造影特征及定量参数对比研究[J].中国临床医学影像杂志,2019,30(4):261-266.
[16] LiZ,RenM,TianJ,etal.The differences in ultrasound and clinicopathological features between basal-like and normallike subtypes of triple negative breast cancer. PLoS One. 2015.10(3):e0114820.
[17] Yoon GY,Chae EY,Cha JH,etal.Imaging and Clinicopath ologic Features Associated With Pathologic Complete Response in HER2-positive Breast Cancer Receiving Neoadjuvant Chemot herapy With Dual HER2 Blockade.Clin Breast Cancer. 2020. 20(1):25-32.
[18] Bae MS,Shin SU,Ryu HS,et al. Pretreatment MR Imaging Features of Triple-Negative Breast Cancer: Association with Response to Neoadjuvant Chemotherapy and Recurrence-Free Survival.Radiology.2016.281(2):392-400.
[19] Moffa G,Galati F,Collalunga E,etal. Can MRI Biomarkers Predict Triple-Negative Breast Cancer. Diagnostics (Basel).2020.10(12):1090.
Copyright © 2024 李露, 吴文瑛
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License